Allan Price

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Charles Butts, Nevin Murray, Andrew W. Maksymiuk et al. · Journal of Clinical Oncology · 2005 · 421 citations · Full text

Medicine, Immunology, Oncology +17

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

Charles Butts, Andrew W. Maksymiuk, Glenwood Goss et al. · Journal of Cancer Research and Clinical Oncology · 2011 · 197 citations · Full text

Medicine, Immunology, Oncology +17

Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)

J. Belderbos, Lon Uitterhoeve, Nico van Zandwijk et al. · European Journal of Cancer · 2006 · 189 citations

Medicine, Oncology, Radiation Oncology +15

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Andrew Hughes, Mary O’Brien, W. Jeffrey Petty et al. · Journal of Clinical Oncology · 2009 · 142 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13